<DOC>
	<DOCNO>NCT00023322</DOCNO>
	<brief_summary>This study evaluate safety effectiveness long-acting form alpha interferon call pegylated interferon treat hepatitis D virus ( HDV ) infection . HDV infect people already hepatitis B infection . HDV often severe progressive . Alpha interferon standard treatment HDV , give injection day three time week 12 month . However , treatment work everyone , respond usually relapse drug stop . The sustained-release form drug , pegylated interferon , give week . Pegylated interferon effective standard interferon hepatitis C patient , patient experience longer-term improvement . This study evaluate effect pegylated interferon hepatitis D hepatitis B . It determine whether long-term therapy drug improve inflammation scar liver , thereby delay reverse cirrhosis , whether improvement maintain . Patients chronic hepatitis D 6 year old may eligible study . Participants medical evaluation , include history physical examination , blood test , routine urinalysis 24-hour urine collection . Chest X-ray , electrocardiogram , abdominal ultrasound liver biopsy do test do within last year . In addition , depend age individual health status , patient may exercise stress testing , eye examination , hear test , psychiatric consultation . All patient fill health-related quality life questionnaire . Patients receive pegylated interferon injection week blood test measure effect treatment liver HBV HDV level . The medical examination liver biopsy repeat end 12 month . Patients improved treatment may continue therapy long-term . Medical evaluation liver biopsy repeat 3 year 5 year .</brief_summary>
	<brief_title>Pegylated Interferon Treat Chronic Hepatitis D</brief_title>
	<detailed_description>We propose treat 10 20 patient chronic delta hepatitis pegylated alpha interferon five year . Patients chronic delta hepatitis raise serum aminotransferase , HBsAg HDV RNA serum , moderate-to-severe chronic hepatitis liver biopsy HDV antigen enrol . Patients monitor least three month regular test ALT level undergo admission thorough medical evaluation , portal pressure measurement percutaneous liver biopsy treatment . Pegylated interferon start dose 180 mcg weekly . At clinic visit , patient question side effect symptom blood take complete blood count routine liver test ( ALT , AST , alkaline phosphatase , direct total bilirubin , albumin ) . At 12-24 week interval patient undergo physical examination test HBsAg , anti-HBs , HDV RNA , prothrombin time . The dose pegylated interferon adjust base upon side effect change ALT level , aim optimal suppression ALT elevation acceptable tolerance . At 48 week ( one year ) every 96 week ( two year ) thereafter , patient readmitted NIH Clinical Center repeat thorough medical evaluation , portal pressure measurement liver biopsy . The primary endpoint therapy improvement hepatic histology liver biopsy do 3 year pegylated alpha interferon therapy . Several secondary endpoint measure , include change HDV RNA , loss HBsAg , HDV stain liver biopsy , ALT level , change portal pressure , quality life , 1.3 5 year , hepatic histology 1 5 year . Patients maintain pegylated interferon adequately tolerate adequate `` histological response , '' define least 3 point improvement inflammatory score 1 point improvement fibrosis score HAI liver biopsy . Therapy stop : ( 1 ) intolerance alpha interferon ( carefully define ) , ( 2 ) lack improvement hepatic histology 1 , 3 , 5 year therapy ( histological nonresponse ) , ( 3 ) `` complete response , '' i.e . loss HDV RNA HBsAg development anti-HBs .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great equal 18 year , male female Serum alanine aspartate aminotransferase activity upper limit normal ( ALT great 41 AST great 31 U/L ) average three determination take previous 6 month . The mean three determination define 'baseline ' level . Presence antiHDV serum . Evidence chronic hepatitis liver biopsy do within previous 12 month necroinflammatory score histology activity index least 5 ( maximum 18 ) least 1 hepatic fibrosis ( maximum 6 ) . Presence HDV antigen liver tissue . Written informed consent . Previous standard alpha interferon antiviral activity exclude patient . Active HBV replication exclude patient . All ethnicity . Patients need meet first six entry criterion enroll . EXCLUSION CRITERIA : Decompensated liver disease , mark bilirubin great 4 mg % , albumin less 3.0 gm % , prothrombin time great 2 sec prolong , history bleed esophageal varix , ascites hepatic encephalopathy . Patients ALT level great 1000 U/L ( great 25 time ULN ) enrol may follow three determination level . Pregnancy , woman childbearing potential spouse woman , inability practice adequate contraception define vasectomy men , tubal ligation woman , use condom spermicide , birth control pill , intrauterine device , DepoProvera , Norplant . Significant systemic major illness liver disease , include , limited , congestive heart failure , renal failure ( creatinine clearance le 50 ml/min ) , organ transplantation , serious psychiatric disease depression ( felt high risk NIH psychiatric consultation service ) , angina pectoris . Immunosuppressive therapy within last 6 month . Evidence another form liver disease addition viral hepatitis ( example autoimmune liver disease , Wilson 's disease , alcoholic liver disease , hemochromatosis , alpha1antitrypsin deficiency ) . Any evidence coronary artery disease cerebral vascular disease , include abnormality exercise stress test patient define risk factor screen evidence underlie coronary artery disease . Active substance abuse , alcohol , inhale injection drug within previous year . Evidence hepatocellular carcinoma ; either alphafetoprotein ( AFP ) level great 200 ng/ml ( normal less 9 ng/ml ) and/or ultrasound ( image study ) demonstrate mass suggestive liver cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>Chronic Hepatitis</keyword>
	<keyword>Alpha Interferon</keyword>
	<keyword>Hepatitis D Virus</keyword>
	<keyword>Delta Hepatitis</keyword>
	<keyword>Viral Hepatitis</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Hepatitis D</keyword>
	<keyword>HDV</keyword>
	<keyword>Liver</keyword>
	<keyword>Hepatitis</keyword>
</DOC>